怀孕期间因克列受体激动症:对母亲和婴儿的影响
Laura Dearden1, Susan E Ozanne1,2
1University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Cambridge, U.K.
Clinical science (London, England : 1979)
|December 8, 2025
概括
葡萄糖类-1 (GLP-1) 受体激动剂在怀孕期间治疗肥胖和妊娠期糖尿病方面表现有前途. 新出现的数据表明,对母亲和婴儿健康有潜在的益处,需要进一步调查.
科学领域:
- 生殖内分泌学 生殖内分泌学
- 孕产妇和胎儿医学 孕产妇和胎儿医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肥胖和妊娠期糖尿病 (GDM) 在怀孕期间存在重大风险.
- 类似于葡萄糖类-1 (GLP-1) 的类似物对肥胖和代谢疾病有效,但它们在怀孕期间的使用尚未得到充分研究.
- 在生育年龄的女性中,增加GLP-1受体激活剂 (GLP1RAs) 的使用,如塞马格卢提德,导致意外怀孕和胎儿暴露.
研究的目的:
- 审查当前关于在怀孕期间使用塞马格卢提德的文献.
- 探索GLP1RAs在产前期对母亲和后代健康的潜在影响.
- 评估GLP1RAs对孕妇肥胖和GDM的影响.
主要方法:
- 关于GLP1RA在怀孕期间使用现有研究的文献综述.
- 关于GLP1RA对胎儿发育的影响的动物研究分析.
- 检查有关胎儿暴露于GLP1RAs的新出现的人类病例报告.
主要成果:
- 动物研究表明GLP1RAs可以改变胎儿生长和新生儿发育.
- 新出现的人类病例报告表明,由于未计划的GLP1RA暴露,胎儿没有明显的伤害.
- 对于孕产妇肥胖和孕期GDM,GLP1RAs的潜在益处在很大程度上仍未被探索.
结论:
- GLP1RAs有可能改善肥胖和GDM复杂的怀孕中母亲和婴儿的结果.
- 进一步的研究对于了解GLP1RAs在怀孕期间的安全性和有效性至关重要.
- 胎儿暴露的发病率不断上升,迫切需要对围产期GLP1RA的使用进行评估.
相关概念视频
Glucagon-like Receptor Agonists
820
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
820
Teratogenicity
3.9K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.9K
Pathophysiology of Diabetes
3.1K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.1K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
857
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
857
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Drug-Receptor Interaction: Agonist
3.7K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
3.7K


